Top

Published in:

Open Access 01-12-2016 | Retraction Note

Retraction Note: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma

Authors: Alireza Mirghasemi, Afshin Taheriazam, Seyyed Hasan Karbasy, Ali Torkaman, Mohammadreza Shakeri, Emad Yahaghi, Aram Mokarizadeh

Published in: Cancer Cell International | Issue 1/2016

Excerpt

The Editors-in-Chief and Publisher have retracted this article [1] because the scientific integrity of the content cannot be guaranteed. An investigation by the Publisher found it to be one of a group of articles we have identified as showing evidence suggestive of attempts to subvert the peer review and publication system to inappropriately obtain or allocate authorship. This article showed evidence of plagiarism (most notably from the articles cited [2, 3]) and authorship manipulation. …

Mirghasemi A, Taheriazam A, Karbasy SH, Torkaman A, Shakeri M, Yahaghi E, Mokarizadeh A. Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma. Cancer Cell Int. 2015;15:86. doi:10.1186/s12935-015-0237-6.CrossRefPubMedPubMedCentral

Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, Wang Z, Wang Z, Cheng P, Tong D, Li C, Tang H. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone. 2013;56(1):220–6.CrossRefPubMed

Bassampour SA, Abdi R, Bahador R, Shakeri M, Torkaman A, Yahaghi E, Taheriazam A. Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival. Tumor Biol. 2015. doi:10.1007/s13277-015-3918-9 (epub ahead of print).

Title: Retraction Note: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma
Authors: Alireza Mirghasemi
Afshin Taheriazam
Seyyed Hasan Karbasy
Ali Torkaman
Mohammadreza Shakeri
Emad Yahaghi
Aram Mokarizadeh
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-016-0359-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Retraction Note to: Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: an Clinico-Cytohistopathological study with environmental factors influencing public health and medicine

MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen

The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer

Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells

Erratum to: Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer